The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 10, 2024

Filed:

Dec. 16, 2021
Applicant:

Intarcia Therapeutics, Inc., Boston, MA (US);

Inventors:

William Blackwell, Boston, MA (US);

Ved P. Srivastava, Boston, MA (US);

Mark Paulik, Boston, MA (US);

Assignee:

I2O Therapeutics, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 9/00 (2006.01); A61K 38/26 (2006.01); A61P 1/16 (2006.01); A61P 1/18 (2006.01); A61P 3/04 (2006.01); A61P 25/00 (2006.01); C07K 14/605 (2006.01);
U.S. Cl.
CPC ...
C07K 14/605 (2013.01); A61K 9/0004 (2013.01); A61K 38/26 (2013.01); A61P 1/16 (2018.01); A61P 3/04 (2018.01);
Abstract

This invention relates to isolated polypeptides that are long acting analogs of human GLP-1. The disclosed GLP-1 receptor agonist polypeptides have beneficial physicochemical properties relative to endogenous GLP-1 and known synthetic GLP-1 receptor agonist polypeptides, such as longer (i.e., 'long-acting') elimination half-lives (t), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed GLP-1 receptor agonist polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed GLP-1 receptor agonist polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).


Find Patent Forward Citations

Loading…